CJC-1295: The Complete Guide (2026)

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a naturally occurring hormone that stimulates the pituitary gland to produce and release growth hormone. It was originally developed by ConjuChem Biotechnologies and consists of 29 amino acids — a modified version of the first 29 amino acids of endogenous GHRH (sometimes referred to as GRF 1-29).

CJC-1295 is available in two primary forms: with Drug Affinity Complex (DAC) and without DAC (sometimes called modified GRF 1-29 or MOD GRF 1-29). The DAC modification allows the peptide to bind to serum albumin in the bloodstream, significantly extending its half-life from minutes to several days. This distinction has important implications for dosing frequency and the nature of growth hormone release.

While CJC-1295 has been the subject of clinical research examining its effects on growth hormone secretion, it is not approved by the FDA for any medical use. It is currently classified as a research peptide and has generated significant interest among researchers studying growth hormone physiology and related applications.

How Does CJC-1295 Work?

CJC-1295 functions as a GHRH mimetic, meaning it mimics the action of the body's natural growth hormone-releasing hormone. Its primary mechanism involves binding to GHRH receptors on the anterior pituitary gland, stimulating the synthesis and secretion of growth hormone (GH).

Pituitary Stimulation

Unlike exogenous growth hormone (which directly supplies GH from an external source), CJC-1295 works by signaling the pituitary gland to produce its own growth hormone. This approach is considered by researchers to be more physiological, as it preserves the body's natural feedback mechanisms and pulsatile release pattern of GH to a greater degree.

GH Pulse Amplification

Research suggests that CJC-1295 amplifies the natural pulses of growth hormone rather than creating a constant, non-physiological elevation. Published studies have reported sustained elevations in GH and IGF-1 (insulin-like growth factor 1) levels following administration, with the duration depending on whether the DAC or no-DAC version is used.

IGF-1 Elevation

Growth hormone stimulates the liver to produce IGF-1, a key mediator of many of GH's downstream effects. Clinical data from early-phase trials with CJC-1295 (with DAC) reported significant increases in IGF-1 levels that remained elevated for an extended period following a single dose. IGF-1 plays important roles in tissue growth, repair, and metabolic regulation.

Synergy with GHRPs

In the research community, CJC-1295 is frequently discussed in combination with growth hormone-releasing peptides (GHRPs) such as Ipamorelin or GHRP-6. The rationale is that GHRH analogs (like CJC-1295) and GHRPs act through different receptor pathways, and their combined use may produce a synergistic effect on growth hormone output that exceeds what either peptide achieves alone.

CJC-1295 with DAC vs Without DAC

Understanding the distinction between these two forms is essential for researchers, as they differ significantly in pharmacokinetics and dosing considerations.

CJC-1295 with DAC

The Drug Affinity Complex (DAC) modification allows CJC-1295 to bind to albumin in the blood, dramatically extending its active life in the body. Key characteristics include:

• Half-life: Approximately 6–8 days, owing to the albumin-binding DAC modification
• GH release pattern: Produces a more sustained, continuous elevation of growth hormone levels rather than sharp pulses
• Dosing frequency: Typically discussed in research protocols as once or twice per week due to the extended half-life
• Convenience: Less frequent administration required compared to the no-DAC version

CJC-1295 without DAC (MOD GRF 1-29)

The version without DAC has a much shorter active window and behaves differently in the body:

• Half-life: Approximately 30 minutes, similar to endogenous GHRH
• GH release pattern: Produces sharper, more pronounced GH pulses that more closely mimic the body's natural pulsatile release
• Dosing frequency: Typically discussed in research protocols as 1–3 times daily, often timed around sleep or training
• Pulsatile release: Considered by some researchers to be more physiological due to its similarity to natural GH secretion patterns

Which Version Is Right for Research?

The choice between DAC and no-DAC versions depends on the specific research objectives. CJC-1295 with DAC offers convenience and sustained GH elevation, while the no-DAC version provides more control over GH pulse timing. Many researchers prefer the no-DAC version when combining with GHRPs like Ipamorelin, as it allows for timed, synergistic pulses. Neither version has been approved for clinical use.

Potential Benefits

The following potential benefits are based on published research and the known physiological effects of elevated growth hormone and IGF-1 levels. Human clinical data specific to CJC-1295 is limited, and these should not be interpreted as guaranteed outcomes.

Growth Hormone Elevation

The primary function of CJC-1295 is to stimulate increased production of growth hormone from the pituitary gland. Published clinical data has demonstrated that CJC-1295 (with DAC) can produce dose-dependent increases in GH and IGF-1 levels. This sustained elevation is the basis for most of the downstream benefits attributed to the peptide in the research literature.

Body Composition

Growth hormone is known to play a significant role in body composition. Research into GH-related therapies has demonstrated associations between elevated GH/IGF-1 levels and reduced body fat (particularly visceral fat) as well as increased lean muscle mass. While direct long-term body composition data for CJC-1295 specifically is limited, its ability to elevate GH levels suggests potential relevance in this area of study.

Recovery & Tissue Repair

Growth hormone and IGF-1 are well-established mediators of tissue repair and recovery. Elevated levels of these hormones are associated with improved collagen synthesis, faster wound healing, and enhanced recovery from physical exertion. Researchers studying CJC-1295 have noted its potential relevance to recovery-focused applications, though direct clinical evidence remains limited.

Sleep Quality

The largest natural GH pulse occurs during deep sleep, and GH is intimately linked to sleep architecture. Some researchers and community reports suggest that GHRH analogs like CJC-1295 (particularly the no-DAC version dosed before bed) may support deeper, more restorative sleep. This is an area of interest that requires further controlled research.

Anti-Aging Research

Growth hormone levels naturally decline with age — a phenomenon sometimes called somatopause. Research into restoring more youthful GH levels has been a significant area of interest in aging science. CJC-1295 has attracted attention in this context as a potential method for supporting GH production without directly administering exogenous growth hormone. Potential anti-aging markers of interest include skin elasticity, bone density, and cognitive function, though clinical data specific to CJC-1295 in these areas is not yet established.

Dosage Guidelines

Disclaimer: The following information is based on protocols described in published research literature and community reports. This is not medical advice. Always consult a healthcare professional before using any research compound.

CJC-1295 with DAC Protocols

Due to its extended half-life, CJC-1295 with DAC is typically discussed at lower frequency dosing schedules:

• Common dosage range: 1,000mcg – 2,000mcg per week
• Frequency: Once or twice per week (e.g., 1,000mcg every 3–4 days)
• Administration: Subcutaneous injection
• Cycle length: Research protocols typically describe use over 8–12 weeks

CJC-1295 without DAC (MOD GRF 1-29) Protocols

The shorter half-life of the no-DAC version requires more frequent dosing to maintain elevated GH levels:

• Common dosage range: 100mcg – 300mcg per dose
• Frequency: 1–3 times daily (commonly before bed, upon waking, and/or post-workout)
• Administration: Subcutaneous injection
• Combination use: Frequently paired with a GHRP (e.g., Ipamorelin at 100–300mcg) at the same time of dosing
• Cycle length: Research protocols typically describe use over 8–16 weeks

Timing Considerations

For the no-DAC version, timing is considered important by many researchers. GH secretion is naturally influenced by factors such as sleep, fasting, and exercise. Common timing recommendations in community protocols include:

• Before bed: To coincide with the body's largest natural GH pulse during deep sleep
• Upon waking (fasted): Fasting states are associated with increased GH sensitivity
• Post-workout: The post-exercise window may support enhanced GH release
• Avoid dosing near meals: Elevated blood sugar and insulin may blunt GH release

Side Effects & Safety

CJC-1295 has been evaluated in early-phase clinical trials, which provide some human safety data. However, comprehensive long-term safety data from large-scale trials is not available.

Commonly Reported Side Effects

Based on clinical data and community reports, the most frequently mentioned side effects include:

• Water retention: Mild fluid retention is one of the most commonly reported effects, particularly in the initial weeks of use. This is consistent with the known effects of elevated GH levels.
• Numbness or tingling: Some users report transient numbness or tingling in the extremities (hands and feet), which may be related to fluid shifts or GH-mediated effects on nerve tissue.
• Flushing: A warm sensation or flushing of the skin shortly after injection has been reported, particularly with higher doses. This typically subsides within 15–30 minutes.
• Injection site reactions: Redness, soreness, or mild irritation at the injection site is common with subcutaneous peptide administration.
• Fatigue or drowsiness: Some users report increased tiredness, particularly when dosing before bed. This may be related to GH's role in sleep regulation.

Important Safety Considerations

• Not FDA-approved: CJC-1295 is not approved for human use by the FDA or any other regulatory body. It is sold as a research chemical.
• GH-related concerns: Prolonged supraphysiological elevation of GH and IGF-1 carries theoretical risks, including potential effects on insulin sensitivity and cell proliferation. These concerns are relevant to any approach that significantly elevates GH levels.
• Limited long-term data: While early-phase clinical data exists, the long-term effects of CJC-1295 use in humans are not well characterized.
• Potential interactions: The effects of CJC-1295 in combination with other compounds have not been thoroughly studied in controlled settings. Individuals with existing health conditions should exercise particular caution.
• Quality control: As with all research peptides, product quality can vary significantly between vendors. Third-party testing is essential to verify purity and identity.

Where to Buy CJC-1295

Sourcing high-quality CJC-1295 is critical. The research peptide market includes vendors of varying quality, and purchasing from an unreliable source can mean receiving underdosed, degraded, or contaminated product. Here are our top recommended vendors for 2026, evaluated on purity, third-party testing, pricing, and customer service.

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. This helps support our independent research and content. We only recommend vendors we have vetted and trust.

Frequently Asked Questions